BAZ2A (TIP5) is involved in epigenetic alterations in prostate cancer and its overexpression predicts disease recurrence

Gu, Lei; Frommel, Sandra C; Oakes, Christopher C; Simon, Ronald; Grupp, Katharina; Gerig, Cristina Y; Bär, Dominik; Robinson, Mark D; Baer, Constance; Weiss, Melanie; Gu, Zuguang; Schapira, Matthieu; Kuner, Ruprecht; Sültmann, Holger; Provenzano, Maurizio; Yaspo, Marie-Laure; Brors, Benedikt; Korbel, Jan; Schlomm, Thorsten; Sauter, Guido

doi:10.1038/ng.3165

Citations

Citation copied

Gu, L., Frommel, S. C., Oakes, C. C., Simon, R., Grupp, K., Gerig, C. Y., Bär, D., Robinson, M. D., Baer, C., Weiss, M., Gu, Z., Schapira, M., Kuner, R., Sültmann, H., Provenzano, M., Yaspo, M.-L., Brors, B., Korbel, J., Schlomm, T., … Santoro, R. (2015). BAZ2A (TIP5) is involved in epigenetic alterations in prostate cancer and its overexpression predicts disease recurrence. Nature Genetics, 47(1), 22–30. https://doi.org/10.1038/ng.3165

Abstract

Prostate cancer is driven by a combination of genetic and/or epigenetic alterations. Epigenetic alterations are frequently observed in all human cancers, yet how aberrant epigenetic signatures are established is poorly understood. Here we show that the gene encoding BAZ2A (TIP5), a factor previously implicated in epigenetic rRNA gene silencing, is overexpressed in prostate cancer and is paradoxically involved in maintaining prostate cancer cell growth, a feature specific to cancer cells. BAZ2A regulates numerous protein-coding genes a